Glenmark Pharmaceuticals’ (Glenmark) novel chemical entity (NCE) ‘GRC 17536’ has successfully completed Phase I trials (single ascending dose and multiple ascending dose) in the Netherlands. GRC 17536 is a global first-in-class program targeting the TRPA1 receptor antagonists for pain and respiratory disorders. TRPA1 belongs to transient receptor potential (TRP) family of ion channels, which have generated a lot of interest as pain targets due to their distinguishing role in peripheral and/or central pain signal transmission.
Glenmark has now planned to initiate Phase II studies in pain indications. The company has filed regulatory submissions with the MHRA, UK, and BfArM, Germany, to initiate Phase 2a proof-of-concept study in patients with painful diabetic peripheral neuropathy. This double-blind, parallel group, placebo controlled study is designed to provide efficacy endpoints upon several weeks of dosing. The projected start of the study is March 2012, subject to regulatory approvals.
Additionally, GRC 17536 will be tested via the inhaled route for use in the respiratory indications. The company has observed good efficacy for GRC 17536 when administered via inhaled route in preclinical pharmacology studies. Phase 1 enabling toxicity studies via inhalation route for GRC 17536 are nearing completion. Glenmark aims to initiate human inhalation studies by June 2012 with an integrated Phase 1/2a protocol in healthy adult volunteers and mild asthmatics followed by an allergen challenge study in patients with mild asthma.
Glenmark Pharmaceuticals, a leader among the emerging market companies in drug discovery and development and most of its active substances in the pipeline are first-in-Class. Glenmark’s achievements over the year include a major deal with Sanofi in Crohn's disease, completing Phase II trials of its first novel product, crofelemer and demonstrated higher sales and profit growth.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1854.15 |
| Dr. Reddys Lab | 1350.75 |
| Cipla | 1497.80 |
| Lupin | 2357.65 |
| Zydus Lifesciences | 1001.20 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
